share_log

NKGen Biotech Presents Novel Manufacturing And Cryopreservation Process For Allogeneic NK Cell Therapy SNK02; CEO Dr. Paul Y. Song Updates On Initial Phase 1 Results For Treating Advanced Refractory Solid Tumors

Benzinga ·  Jun 13 01:07
NKGen Biotech Presents Novel Manufacturing And Cryopreservation Process For Allogeneic NK Cell Therapy SNK02; CEO Dr. Paul Y. Song Updates On Initial Phase 1 Results For Treating Advanced Refractory Solid Tumors
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment